MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells

Abstract Background Trastuzumab (TZ) resistance remains a significant challenge in the treatment of human epidermal growth factor receptor 2 (HER2)-positive epithelial ovarian cancer (EOC), necessitating novel therapeutic strategies to improve treatment efficacy. Functionalized gold nanoparticles (A...

Full description

Saved in:
Bibliographic Details
Main Authors: Tommaso A. Salamone, Sofia Marotta, Stella Mrmić, Salvatore Raffa, Sara Cerra, Beatrice Pennacchi, Martina Mercurio, Vincenzo Visco, Maurizio Alimandi, Maria Rosaria Ricciardi, Maurizio Taurino, Ilaria Fratoddi, Pankaj Trivedi, Eleni Anastasiadou
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Cancer Nanotechnology
Subjects:
Online Access:https://doi.org/10.1186/s12645-025-00330-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849767039094226944
author Tommaso A. Salamone
Sofia Marotta
Stella Mrmić
Salvatore Raffa
Sara Cerra
Beatrice Pennacchi
Martina Mercurio
Vincenzo Visco
Maurizio Alimandi
Maria Rosaria Ricciardi
Maurizio Taurino
Ilaria Fratoddi
Pankaj Trivedi
Eleni Anastasiadou
author_facet Tommaso A. Salamone
Sofia Marotta
Stella Mrmić
Salvatore Raffa
Sara Cerra
Beatrice Pennacchi
Martina Mercurio
Vincenzo Visco
Maurizio Alimandi
Maria Rosaria Ricciardi
Maurizio Taurino
Ilaria Fratoddi
Pankaj Trivedi
Eleni Anastasiadou
author_sort Tommaso A. Salamone
collection DOAJ
description Abstract Background Trastuzumab (TZ) resistance remains a significant challenge in the treatment of human epidermal growth factor receptor 2 (HER2)-positive epithelial ovarian cancer (EOC), necessitating novel therapeutic strategies to improve treatment efficacy. Functionalized gold nanoparticles (AuNPs) constitute a promising platform for drug delivery and the ability to enhance tumor targeting via the enhanced permeability and retention (EPR) effect. miR-200c, a well-established tumor suppressor microRNA (miRNA), plays a crucial role in inhibiting epithelial-mesenchymal transition (EMT). However, its role in modulating HER2 signaling pathways and sensitizing ovarian cancer cells to TZ remains largely unexplored. Here, we investigate for the first time the combinatorial effect of miR-200c and thiol-functionalized AuNPs (< 10 nm) loaded with TZ (AuNPs-TZ) in overcoming TZ resistance and enhancing treatment efficacy in ovarian cancer cells. Results Pristine AuNPs were not cytotoxic, confirming their biocompatibility as a nanocarrier for TZ delivery. AuNPs were loaded noncovalently with TZ and maintained colloidal stability to prevent aggregation while facilitating effective cellular uptake. Treatment of ovarian cancer cells overexpressing miR-200c with AuNPs-TZ significantly reduced cell viability and increased apoptosis. Immunoblot analysis showed a reduction of phosphorylated HER2 and downstream Kirsten Rat Sarcoma Virus (KRAS) signaling. Furthermore, transmission electron microscopy (TEM) demonstrated morphological changes in miR-200c-transfected ovarian cancer cells and confirmed the localization of AuNPs carrying TZs on the cell membrane and in the cytoplasm. Conclusions These findings highlight the potential of AuNPs-TZ delivery combined with miR-200c as a promising therapeutic strategy to improve the response of HER2-positive EOC to TZ treatment. These results imply the need to further develop AuNP/miRNA-based combinatorial therapies as a viable nanomedicine approach for drug-resistant cancers. Graphical Abstract
format Article
id doaj-art-007db6c8469547b69e721ee37cfef693
institution DOAJ
issn 1868-6958
1868-6966
language English
publishDate 2025-06-01
publisher BMC
record_format Article
series Cancer Nanotechnology
spelling doaj-art-007db6c8469547b69e721ee37cfef6932025-08-20T03:04:22ZengBMCCancer Nanotechnology1868-69581868-69662025-06-0116111910.1186/s12645-025-00330-5MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cellsTommaso A. Salamone0Sofia Marotta1Stella Mrmić2Salvatore Raffa3Sara Cerra4Beatrice Pennacchi5Martina Mercurio6Vincenzo Visco7Maurizio Alimandi8Maria Rosaria Ricciardi9Maurizio Taurino10Ilaria Fratoddi11Pankaj Trivedi12Eleni Anastasiadou13Department of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Chemistry, Sapienza University of RomeDepartment of Chemistry, Sapienza University of RomeDepartment of Chemistry, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeDepartment of Chemistry, Sapienza University of RomeDepartment of Experimental Medicine, Sapienza University of RomeDepartment of Clinical and Molecular Medicine, Sapienza University of RomeAbstract Background Trastuzumab (TZ) resistance remains a significant challenge in the treatment of human epidermal growth factor receptor 2 (HER2)-positive epithelial ovarian cancer (EOC), necessitating novel therapeutic strategies to improve treatment efficacy. Functionalized gold nanoparticles (AuNPs) constitute a promising platform for drug delivery and the ability to enhance tumor targeting via the enhanced permeability and retention (EPR) effect. miR-200c, a well-established tumor suppressor microRNA (miRNA), plays a crucial role in inhibiting epithelial-mesenchymal transition (EMT). However, its role in modulating HER2 signaling pathways and sensitizing ovarian cancer cells to TZ remains largely unexplored. Here, we investigate for the first time the combinatorial effect of miR-200c and thiol-functionalized AuNPs (< 10 nm) loaded with TZ (AuNPs-TZ) in overcoming TZ resistance and enhancing treatment efficacy in ovarian cancer cells. Results Pristine AuNPs were not cytotoxic, confirming their biocompatibility as a nanocarrier for TZ delivery. AuNPs were loaded noncovalently with TZ and maintained colloidal stability to prevent aggregation while facilitating effective cellular uptake. Treatment of ovarian cancer cells overexpressing miR-200c with AuNPs-TZ significantly reduced cell viability and increased apoptosis. Immunoblot analysis showed a reduction of phosphorylated HER2 and downstream Kirsten Rat Sarcoma Virus (KRAS) signaling. Furthermore, transmission electron microscopy (TEM) demonstrated morphological changes in miR-200c-transfected ovarian cancer cells and confirmed the localization of AuNPs carrying TZs on the cell membrane and in the cytoplasm. Conclusions These findings highlight the potential of AuNPs-TZ delivery combined with miR-200c as a promising therapeutic strategy to improve the response of HER2-positive EOC to TZ treatment. These results imply the need to further develop AuNP/miRNA-based combinatorial therapies as a viable nanomedicine approach for drug-resistant cancers. Graphical Abstracthttps://doi.org/10.1186/s12645-025-00330-5TrastuzumabHER2AuNPsMicroRNAOvarian cancerDrug delivery
spellingShingle Tommaso A. Salamone
Sofia Marotta
Stella Mrmić
Salvatore Raffa
Sara Cerra
Beatrice Pennacchi
Martina Mercurio
Vincenzo Visco
Maurizio Alimandi
Maria Rosaria Ricciardi
Maurizio Taurino
Ilaria Fratoddi
Pankaj Trivedi
Eleni Anastasiadou
MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells
Cancer Nanotechnology
Trastuzumab
HER2
AuNPs
MicroRNA
Ovarian cancer
Drug delivery
title MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells
title_full MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells
title_fullStr MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells
title_full_unstemmed MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells
title_short MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells
title_sort mir 200c synergizes with trastuzumab loaded gold nanoparticles to overcome resistance in ovarian cancer cells
topic Trastuzumab
HER2
AuNPs
MicroRNA
Ovarian cancer
Drug delivery
url https://doi.org/10.1186/s12645-025-00330-5
work_keys_str_mv AT tommasoasalamone mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT sofiamarotta mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT stellamrmic mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT salvatoreraffa mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT saracerra mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT beatricepennacchi mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT martinamercurio mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT vincenzovisco mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT maurizioalimandi mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT mariarosariaricciardi mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT mauriziotaurino mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT ilariafratoddi mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT pankajtrivedi mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells
AT elenianastasiadou mir200csynergizeswithtrastuzumabloadedgoldnanoparticlestoovercomeresistanceinovariancancercells